United Therapeutics Corporation $UTHR Position Trimmed by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 12.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 235,721 shares of the biotechnology company’s stock after selling 32,131 shares during the quarter. Pictet Asset Management Holding SA’s holdings in United Therapeutics were worth $127,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in UTHR. Callan Family Office LLC bought a new stake in United Therapeutics in the second quarter worth $1,217,000. Andra AP fonden raised its stake in United Therapeutics by 33.5% during the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock valued at $18,912,000 after purchasing an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in United Therapeutics during the second quarter valued at $3,359,000. Partners Capital Investment Group LLP bought a new position in United Therapeutics during the second quarter valued at $1,691,000. Finally, Palo Alto Investors LP bought a new position in United Therapeutics during the second quarter valued at $33,911,514. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $562.02 on Monday. The company has a market cap of $23.94 billion, a P/E ratio of 21.21, a P/E/G ratio of 3.78 and a beta of 0.49. The business’s 50 day moving average price is $533.99 and its 200-day moving average price is $533.42. United Therapeutics Corporation has a fifty-two week low of $444.04 and a fifty-two week high of $614.23.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $7.16 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 24.77 EPS for the current year.

United Therapeutics declared that its Board of Directors has approved a stock repurchase plan on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This buyback authorization permits the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 401,528 shares of company stock worth $213,440,124 in the last quarter. Insiders own 8.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. TD Cowen upped their target price on shares of United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group set a $725.00 target price on shares of United Therapeutics in a research report on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 price target on shares of United Therapeutics in a report on Wednesday, October 14th. Finally, Raymond James Financial set a $720.00 price target on United Therapeutics in a research report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $676.40.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

United Therapeutics Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.